Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexaria Bioscience (LEXX) EBIT Margin (2017 - 2025)

Lexaria Bioscience's EBIT Margin history spans 9 years, with the latest figure at 1545.17% for Q3 2025.

  • For Q3 2025, EBIT Margin rose 107752.0% year-over-year to 1545.17%; the TTM value through Nov 2025 reached 2062.0%, down 59202.0%, while the annual FY2025 figure was 1683.01%, 44385.0% down from the prior year.
  • EBIT Margin for Q3 2025 was 1545.17% at Lexaria Bioscience, up from 2155.41% in the prior quarter.
  • Across five years, EBIT Margin topped out at 13.92% in Q2 2022 and bottomed at 21142.2% in Q4 2023.
  • The 5-year median for EBIT Margin is 1545.17% (2025), against an average of 3265.64%.
  • The largest annual shift saw EBIT Margin plummeted -1940749bps in 2023 before it surged 1967925bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 14434.31% in 2021, then surged by 88bps to 1734.71% in 2022, then tumbled by -1119bps to 21142.2% in 2023, then skyrocketed by 93bps to 1462.95% in 2024, then dropped by -6bps to 1545.17% in 2025.
  • Per Business Quant, the three most recent readings for LEXX's EBIT Margin are 1545.17% (Q3 2025), 2155.41% (Q2 2025), and 1581.04% (Q1 2025).